During the past decade, IMMUNOe International Research Centers conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 3 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "IMMUNOe International Research Centers" are "Primary Immunodeficiency Diseases (PID)" (2 trials), "Alzheimer's Disease" (1 trials) and "Atopic Dermatitis" (1 trials). Many other conditions were trialed in "IMMUNOe International Research Centers" in a lesser frequency.

Most popular intervention types in "IMMUNOe International Research Centers" are "Biological" (2 trials) and "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Aducanumab (BIIB037)" (1 trials), "HYQVIA" (1 trials), "Immune Globulin Infusion (Human), 10%" (1 trials), "Pimecrolimus Cream 1% (Valeant)" (1 trials) and "Pimecrolimus Cream, 1%" (1 trials). Other intervention names were less common.

The vast majority of trials in "IMMUNOe International Research Centers" are 4 trials for "All" genders.

Currently, there are NaN active trials in "IMMUNOe International Research Centers". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in IMMUNOe International Research Centers, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in IMMUNOe International Research Centers, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".